
Melhoria da função neuropsicológica com o tratamento com memantina em pacientes com lúpus eritematoso sistêmico: um ensaio clínico randomizado controlado com placebo de fase 2
ReumatologiaResumo original em inglês
O que aconteceu
Neuropsychological symptoms are common, disabling manifestations of systemic lupus erythematosus (SLE) that can persist despite immunomodulatory treatment. We evaluated whether the N-methyl-D-aspartate receptor (NMDAR) antagonist, memantine, improves cognitive function in individuals with SLE and neuropsychological dysfunction.
ClearMEMory (NCT03527472) was a multisite, randomised, placebo-controlled 12-week clinical trial of memantine titrated to 40 mg/d among adults with SLE with objective neuropsychological dysfunction. The primary outcome was change in the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total score from baseline to week 12. Additional outcomes included change in RBANS total score above a threshold considered clinically important (score increase ≥8) and patient global impression of change (PGI-C).
O que encontraram
Of 131 patients screened, 56 were randomised, and 43 completed primary outcome assessment and were analysed, including 18 in the memantine group and 25 in the placebo group. Improvement in RBANS total score between baseline and week 12 was greater in the memantine group (median change: +8) than the placebo group (median change: +5) (P = .032); 12 (66.7%) participants in the memantine group and 9 (36.0%) participants in the placebo group had an increase in total RBANS score ≥8 (P = .047) (number-needed-to-treat = 3.3). Using the PGI-C, 61% of participants in the memantine group and 36% of participants in the placebo group self-reported improvement (P = .19). Discontinuation due to adverse events occurred in 5 (19%) participants in the memantine group and 5 (17%) participants in the placebo group.
Por que isso importa
Among patients with SLE-associated neuropsychological dysfunction, treatment with memantine for 12 weeks improved objective neuropsychological function.
Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.
O estudo original
Improvement in neuropsychological function with memantine treatment among patients with systemic lupus erythematosus: a phase 2 randomised placebo-controlled clinical trial
Jillian P Rhoads, Lillian N Ahmad, Jonathan Williams, Liping Du, Emily A Littlejohn, Meera G Subash, Jana K Shirey-Rice, Jill M Pulley, Wesley H Self, Erin M Collar et al.
Descritores MeSH
- Lupus Erythematosus, Systemic
- Memantine
- Excitatory Amino Acid Antagonists
- Female
- Humans
- Cognitive Enhancement
- Middle Aged
- Neuropsychological Tests
- Receptors, N-Methyl-D-Aspartate
- Treatment Outcome